Kheifetz Yuri, Elishmereni Moran, Agur Zvia
Institute for Medical Biomathematics (IMBM), POB 282, Hate'ena St. 10, 60991, Bene-Ataroth, Israel.
J Pharmacokinet Pharmacodyn. 2014 Oct;41(5):479-91. doi: 10.1007/s10928-014-9383-z. Epub 2014 Sep 18.
Inflammation underlies many diseases and is an undesired effect of several therapy modalities. Biomathematical modeling can help unravel the complex inflammatory processes and the mechanisms triggering their emergence. We developed a model for induction of C-reactive protein (CRP), a clinically reliable marker of inflammation, by interleukin (IL)-11, an approved cytokine for treatment of chemotherapy-induced thrombocytopenia. Due to paucity of information on the mechanisms underlying inflammation-induced CRP dynamics, our model was developed by systematically evaluating several models for their ability to retrieve variable CRP profiles observed in IL-11-treated breast cancer patients. The preliminary semi-mechanistic models were designed by non-linear mixed-effects modeling, and were evaluated by various performance criteria, which test goodness-of-fit, parsimony and uniqueness. The best-performing model, a robust population model with minimal inter-individual variability, uncovers new aspects of inflammation dynamics. It shows that CRP clearance is a nonlinear self-controlled process, indicating an adaptive anti-inflammatory reaction in humans. The model also reveals a dual IL-11 effect on CRP elevation, whereby the drug has not only a potent immediate influence on CRP incline, but also a long-term influence inducing elevated CRP levels for several months. Consistent with this, model simulations suggest that periodic IL-11 therapy may result in prolonged low-grade (chronic) inflammation post treatment. Future application of the model can therefore help design improved IL-11 regimens with minimized long-term CRP toxicity. Our study illuminates the dynamics of inflammation and its control, and provides a prototype for progressive modeling of complex biological processes in the medical realm and beyond.
炎症是许多疾病的基础,也是多种治疗方式产生的不良效应。生物数学建模有助于揭示复杂的炎症过程及其引发机制。我们构建了一个模型,用于研究白细胞介素(IL)-11诱导C反应蛋白(CRP)的过程,CRP是一种临床上可靠的炎症标志物,而IL-11是一种已获批准用于治疗化疗引起的血小板减少症的细胞因子。由于关于炎症诱导CRP动态变化机制的信息匮乏,我们通过系统评估多个模型检索在接受IL-11治疗的乳腺癌患者中观察到的可变CRP谱的能力来构建模型。初步的半机制模型通过非线性混合效应建模设计,并通过各种性能标准进行评估,这些标准用于检验拟合优度、简约性和唯一性。表现最佳的模型是一个个体间变异性最小的稳健群体模型,它揭示了炎症动态变化的新方面。该模型表明CRP清除是一个非线性自我控制过程,这表明人体存在适应性抗炎反应。该模型还揭示了IL-11对CRP升高的双重作用,即该药物不仅对CRP上升有强大的即时影响,而且对诱导CRP水平升高数月有长期影响。与此一致的是,模型模拟表明,周期性IL-11治疗可能导致治疗后长期的低度(慢性)炎症。因此,该模型的未来应用有助于设计出长期CRP毒性最小化的改良IL-11治疗方案。我们的研究阐明了炎症的动态变化及其控制,并为医学领域及其他领域复杂生物过程的渐进建模提供了一个原型。